Disclosed is an insulin analogue comprising a B-chain polypeptide incorporating a chlorinated phenylalanine located at position B24 wherein the chlorinated phenylalanine is para-monochloro-phenylalanine. Also disclosed is the use of an insulin analogue or a physiologically acceptable salt thereof for the preparation of a pharmaceutical composition formulated for administration to a patient for lowering of the blood sugar level of the patient, wherein said composition contains a physiologically effective amount of said insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains a B-chain polypeptide incorporating a chlorinated phenylalanine at position B24 wherein the chlorinated phenylalanine is para-monochloro-phenylalanine.
